Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making

Si Ye Chen, Yong Yang, Shu Nan Qi, Ying Wang, Chen Hu, Xia He, Li Ling Zhang, Gang Wu, Bao Lin Qu, Li Ting Qian, Xiao Rong Hou, Fu Quan Zhang, Xue Ying Qiao, Hua Wang, Gao Feng Li, Yu Jing Zhang, Yuan Zhu, Jian Zhong Cao, Sheng Min Lan, Jun Xin WuTao Wu, Su Yu Zhu, Mei Shi, Li Ming Xu, Zhi Yong Yuan, Joachim Yahalom, Richard Tsang, Yu Qin Song, Jun Zhu, Hang Su, Ye Xiong Li

Research output: Contribution to journalArticle

Abstract

Derived from our original nomogram study by using the risk variables from multivariable analyses in the derivation cohort of 1383 patients with extranodal NK/T-cell lymphoma, nasal-type (ENKTCL) who were mostly treated with anthracycline-based chemotherapy, we propose an easily used nomogram-revised risk index (NRI), validated it and compared with Ann Arbor staging, the International Prognostic Index (IPI), Korean Prognostic Index (KPI), and prognostic index of natural killer lymphoma (PINK) for overall survival (OS) prediction by examining calibration, discrimination, and decision curve analysis in a validation cohort of 1582 patients primarily treated with non-anthracycline-based chemotherapy. The calibration of the NRI showed satisfactory for predicting 3- and 5-year OS in the validation cohort. The Harrell’s C-index and integrated Brier score (IBS) of the NRI for OS prediction demonstrated a better performance than that of the Ann Arbor staging system, IPI, KPI, and PINK. Decision curve analysis of the NRI also showed a superior outcome. The NRI is a promising tool for stratifying patients with ENKTCL into risk groups for designing clinical trials and for selecting appropriate individualized treatment.

Original languageEnglish (US)
JournalLeukemia
DOIs
StateAccepted/In press - 2020

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making'. Together they form a unique fingerprint.

  • Cite this

    Chen, S. Y., Yang, Y., Qi, S. N., Wang, Y., Hu, C., He, X., Zhang, L. L., Wu, G., Qu, B. L., Qian, L. T., Hou, X. R., Zhang, F. Q., Qiao, X. Y., Wang, H., Li, G. F., Zhang, Y. J., Zhu, Y., Cao, J. Z., Lan, S. M., ... Li, Y. X. (Accepted/In press). Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia. https://doi.org/10.1038/s41375-020-0791-3